

### **Supplementary appendix**

This appendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Fang T, Al Khleifat A, Meurgey J-H, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. *Lancet Neurol* 2018; published online March 7. [http://dx.doi.org/10.1016/S1474-4422\(18\)30054-1](http://dx.doi.org/10.1016/S1474-4422(18)30054-1).

## Staging algorithm

A regional analysis was performed, using regions defined as Bulbar, Upper limb, Lower limb.

- Stages 1-3 were scored based on the number of affected regions. A region was considered affected if there was a drop in maximum score for that region in any of the relevant scales (Norris bulbar, Norris limb and muscle strength). One affected region = stage 1, two affected regions = stage 2, three affected regions = stage 3. The minimum stage at entry was stage 2 because the minimum El Escorial category at entry was Probable, which requires two regions to be affected.
- Stage 4 was scored if the person had a gastrostomy, defined by the date of insertion, or vital capacity  $\leq 75\%$  predicted value, whichever date fell earlier.
- Stage 5 was scored as the date of death, tracheostomy or intubation, whichever date fell earlier.

The censor date was 31 December 1994. Any events occurring after this date were not recorded and treated as censored.

No stage reversals were allowed.

<b><i>Treatment</i></b>	<b>Stage 2</b>	<b>Stage 3</b>	<b>Stage 4</b>
<i>50mg/day</i>	90	106	41
<i>100mg/day</i>	87	117	32
<i>200mg/day</i>	101	101	42
<i>Placebo</i>	77	127	38

**Supplementary Table 1: Stage at enrolment by treatment group.** There was no significant difference between treatment groups for the number of patients enrolling at each stage ( $P = 0.22$ ).

<i>Treatment combinations vs placebo</i>	<i>P-value</i>
<i>All doses</i>	0.053
<i>Higher doses combined</i>	0.043
<i>All doses combined</i>	0.027

**Supplementary Table 2: Kaplan Meier product limit distribution of the effect of Riluzole on Stage 4 for participants with a stage of enrolment of 2 or 3.** All doses vs placebo (50mg, 100mg, 200mg individually vs placebo), higher doses combined vs placebo (100mg + 200mg vs placebo) and all doses combined vs placebo (50mg + 100mg + 200mg vs placebo).